Insilico study says AI-designed IPF drug rentosertib reverses biological age on six proteomic clocks

PUBT · 1d ago
Insilico study says AI-designed IPF drug rentosertib reverses biological age on six proteomic clocks
  • Insilico Medicine announced a Nature Biotechnology study analyzing Phase IIa rentosertib data in idiopathic pulmonary fibrosis patients.
  • The analysis indicated a consistent reduction in predicted biological age in treated patients versus placebo across multiple independent proteomic aging models.
  • Lung function results in the trial were described as showing a promising dose-related improvement, aligning directionally with the aging-biomarker shift.
  • Results were published ahead of a scheduled presentation at a Nature conference on Sept. 8, 2026.
  • Rentosertib has advanced into a Phase III study, supporting a broader strategy to add aging biomarkers to disease trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609070542PR_NEWS_USPR_____CN41841) on September 07, 2026, and is solely responsible for the information contained therein.